Methyl iodide → HCID 178497765, 화합물
반응식
[CH3:1][O:2][C:3](=[O:32])[C:4]1[CH:9]=[CH:8][CH:7]=[C:6]([CH2:10][N:11]2[CH2:16][CH2:15][CH2:14][C@H:13]([NH:17][C:18]([NH2:31])=[N:19][C:20]([C:22]3[C:27]([NH2:28])=[N:26][C:25]([NH2:29])=[C:24]([Cl:30])[N:23]=3)=[O:21])[CH2:12]2)[CH:5]=1.[CH3:33]I>CC(C)=O.CN(C)C=O>[Cl-:30].[NH2:28][C:27]1[C:22]([C:20]([N:19]=[C:18]([NH2:31])[NH:17][CH:13]2[CH2:14][CH2:15][CH2:16][N@+:11]([CH2:10][C:6]3[CH:7]=[CH:8][CH:9]=[C:4]([C:3]([O:2][CH3:1])=[O:32])[CH:5]=3)([CH3:33])[CH2:12]2)=[O:21])=[N:23][C:24]([Cl:30])=[C:25]([NH2:29])[N:26]=1참가 물질
4
실험 절차
A mixture of 35 mg (0.066 mmol) (S)-3-{3-[N′-(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-guanidino]-piperidin-1-ylmethyl}-benzoic acid methyl ester (intermediate 10) and 100 μl (0.7 mmol) methyl iodide in 2 ml acetone/dimethylformamide (1:1) is stirred at room temperature overnight. Then the reaction mixture is concentrated under reduced pressure and the residue is purified by preparative reverse phase HPLC (gradient of methanol and water+0.2% trifluoroacetic acid, 25° C.). Fractions containing the title compound were concentrated under reduced pressure, treated with excess HCl in methanol and evaporated again.